RxDoctor Payments Data

Pranav Amin, MD

Ophthalmology · Yuba City, CANPI 1609801422

Payments from drug & device makers

$3,437in general payments, 2019–2025

Across 66 payments — averaging $52.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Alcon$530
  • Rxsight Inc$129
  • Sight Sciences, Inc.$113
  • AbbVie$102
  • Biotissue Holdings Inc.$98
  • plus $418 from 10 others

What the payments were for

  • Travel & lodging$1,44742%
  • Food & beverage$1,97057%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,437 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$831,285
Medicare patients
1,763
Services billed
7,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost154$61,920
AlrexLoteprednol Etabonate82$33,298
Prednisolone Acetate817$22,675
VyzultaLatanoprostene Bunod48$17,405
ProlensaBromfenac Sodium39$13,915
Cyclosporine35$12,866
RestasisCyclosporine23$12,488
RocklatanNetarsudil Mesylat/Latanoprost17$11,457
MoxifloxacinMoxifloxacin Hcl496$9,896
RhopressaNetarsudil Mesylate23$9,568
Latanoprost1,019$9,147
Travoprost25$7,432
SimbrinzaBrinzolamide/Brimonidine Tart33$6,929
Ketorolac Tromethamine510$6,889
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$6,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$102$80,160188 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Prolensa, Loteprednol Etabonate$53$51,547152 claims
Bausch & Lomb Americas Inc.Vyzulta$52$17,40548 claims
AlconSimbrinza$530$6,92933 claims
Eyevance Pharmaceuticals LLCFlarex$59$2,15917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Yuba City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →